Antares Pharma (ATRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 14,162 | 12,703 | 14,040 | 15,052 | 13,416 |
| Cost of Goods | 6,960 | 7,186 | 7,107 | 8,523 | 5,617 |
| Gross Profit | 7,202 | 5,517 | 6,933 | 6,529 | 7,799 |
| Operating Expenses | 12,073 | 11,322 | 10,199 | 11,998 | 11,136 |
| Operating Income | -3,911 | -5,619 | -3,159 | -4,946 | -2,720 |
| Interest Expense | 654 | 631 | 629 | 626 | 168 |
| Other Income | 45 | 57 | 74 | 119 | 48 |
| Pre-tax Income | -4,520 | -6,193 | -3,714 | -5,453 | -2,840 |
| Net Income Continuous | -4,520 | -6,193 | -3,714 | -5,453 | -2,840 |
| Net Income | $-4,520 | $-6,193 | $-3,714 | $-5,453 | $-2,840 |
| EPS Basic Total Ops | -0.03 | -0.04 | -0.03 | -0.03 | -0.02 |
| EPS Basic Continuous Ops | -0.03 | -0.04 | -0.02 | -0.03 | -0.02 |
| EPS Diluted Total Ops | -0.03 | -0.04 | -0.03 | -0.03 | -0.02 |
| EPS Diluted Continuous Ops | -0.03 | -0.04 | -0.02 | -0.03 | -0.02 |
| EBITDA(a) | $-3,308 | $-5,015 | $-2,593 | $-4,382 | $-2,240 |